The recommended pralsetinib dose for the treatment of patients with metastatic RET fusion-positive NSCLC or thyroid cancer is 400 mg orally once daily [2,3]; however, a lower dose of 200 mg pralsetinib was administered to subjects enrolled in this study. This evidence concerns the gene RET and thyroid cancer.